Becker A B, Nelson N A, Simons F E
J Pediatr. 1983 Mar;102(3):465-9. doi: 10.1016/s0022-3476(83)80679-9.
In a double-blind trial we compared the efficacy and safety of inhaled salbutamol (albuterol), nebulized with oxygen by face mask, and subcutaneous epinephrine in 40 children with acute asthma. No significant difference between salbutamol and epinephrine was seen at any time for clinical score, respiratory rate, heart rate, blood pressure. PaO2, PaCO2, FVC, FEV1, FEV1/FVC, or FEF25-75%. PaO2 remained unchanged after salbutamol but increased significantly (P less than 0.05) after epinephrine. No significant difference occurred between the groups for repeat treatment, admission on initial visit, return to emergency room, admission on return, or total admissions. Significantly (P less than 0.01) increased adverse effects were seen within the group given epinephrine. We conclude that inhaled nebulized salbutamol and subcutaneous epinephrine are equally effective. In view of the lack of adverse effects and noninvasiveness of inhaled salbutamol, we recommend its use for the treatment of acute asthma in children.
在一项双盲试验中,我们比较了40例急性哮喘儿童使用面罩吸氧雾化吸入沙丁胺醇(舒喘灵)和皮下注射肾上腺素的疗效及安全性。在临床评分、呼吸频率、心率、血压、动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)、用力肺活量(FVC)、第一秒用力呼气容积(FEV1)、FEV1/FVC或25%-75%用力呼气流量(FEF25-75%)方面,沙丁胺醇和肾上腺素在任何时间均无显著差异。沙丁胺醇治疗后PaO2保持不变,但肾上腺素治疗后PaO2显著升高(P<0.05)。两组在重复治疗、首次就诊时入院、返回急诊室、复诊时入院或总入院率方面无显著差异。肾上腺素治疗组的不良反应显著增加(P<0.01)。我们得出结论,吸入雾化沙丁胺醇和皮下注射肾上腺素同样有效。鉴于吸入沙丁胺醇无不良反应且为非侵入性,我们建议将其用于治疗儿童急性哮喘。